Morbidity Factors in Breast Cancer Patients with Venous Access Devices
Author Information
Author(s): İLHAN Burak, KILIÇ Berkay
Primary Institution: İstanbul University
Hypothesis
What are the morbidities associated with the implantation of a totally implantable venous access device (TIVAD) in breast cancer patients?
Conclusion
The right subclavian vein approach is a safe method for TIVAD implantation in breast cancer patients, with low complication rates.
Supporting Evidence
- The incidence of early complications was 2.3% and late complications was 2.6%.
- Ten catheter-related infections were the most common complication.
- Using ultrasound guidance decreased the rate of early complications.
Takeaway
This study looked at how safe it is to put in a special device for giving medicine to breast cancer patients, and it found that doing it in a certain way is usually safe.
Methodology
The study analyzed clinical data and complications in 546 breast cancer patients who received TIVAD between 2017 and 2021.
Potential Biases
Potential biases due to the retrospective design and lack of randomization.
Limitations
The study is retrospective and has a low number of patients.
Participant Demographics
Mean age was 56.1 years, with a mean body mass index of 25.3; 95.9% had right-sided TIVAD.
Statistical Information
P-Value
0.022 for catheter-related infections associated with adjuvant radiotherapy
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website